Publicacións en colaboración con investigadores/as de Universitat de Barcelona (36)

2024

  1. The cellular prion protein does not affect tau seeding and spreading of sarkosyl-insoluble fractions from Alzheimer’s disease

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

2021

  1. An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria

    Redox Biology, Vol. 46

2020

  1. Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates

    Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164

  2. Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum

    Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42

2019

  1. Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings

    Journal of Neurology, Vol. 266, Núm. 10, pp. 2396-2405

  2. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease

    Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910

2018

  1. Alterations in Gene and Protein Expression of Cannabinoid CB 2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims

    Neurotherapeutics, Vol. 15, Núm. 3, pp. 796-806

  2. Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes

    Frontiers in Neuroanatomy, Vol. 12

  3. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia

    Brain, Behavior, and Immunity, Vol. 67, pp. 139-151

  4. Usefulness of identifying g-protein-coupled receptor dimers for diagnosis and therapy of neurodegenerative diseases and of gliomas

    Histology and Histopathology, Vol. 33, Núm. 9, pp. 909-917

2017

  1. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors

    Frontiers in Pharmacology, Vol. 8, Núm. OCT

  2. Neurochemical evidence supporting dopamine D1–D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation

    Brain Structure and Function, Vol. 222, Núm. 4, pp. 1767-1784

2016

  1. Hints on the Lateralization of Dopamine Binding to D 1 Receptors in Rat Striatum

    Molecular Neurobiology, Vol. 53, Núm. 8, pp. 5436-5445

  2. Basic pharmacological and structural evidence for class A G-protein-coupled receptor heteromerization

    Frontiers in Pharmacology, Vol. 7, Núm. MAR

  3. Disruption of a dopamine receptor complex amplifies the actions of cocaine

    European Neuropsychopharmacology, Vol. 26, Núm. 9, pp. 1366-1377

  4. Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration

    Cell Death and Disease, Vol. 7, Núm. 10

  5. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415

  6. Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay

    Journal of Pharmacology and Experimental Therapeutics, Vol. 358, Núm. 3, pp. 580-587

2015

  1. Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism

    Brain Structure and Function, Vol. 220, Núm. 5, pp. 2721-2738